IBio Settles Investor Suit Over Ebola Drug Plans For $1.87M
Pharmaceutical company iBio Inc. settled a putative securities class action in Delaware federal court Thursday, agreeing to pay roughly $1.87 million and attorneys' fees for allegedly fabricating a joint venture to...To view the full article, register now.
Already a subscriber? Click here to view full article